Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.80 |
| ▸ | S1PR3 | Q99500 | 14/20 | 0.80 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275506 | 0.93 | S1PR1 (0.80) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4272571 | 0.90 | S1PR1 (0.86) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4276052 | 0.89 | S1PR1 (0.77) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4274941 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4281220 | 0.89 | S1PR1 (0.84) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4273762 | 0.86 | S1PR1 (0.69) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4279366 | 0.85 | S1PR1 (0.71) | S1PR1S1PR3S1PR5 | |
| SCHEMBL5510818 | 0.85 | S1PR1 (0.73) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4272398 | 0.84 | S1PR1 (0.72) | S1PR1S1PR3S1PR5 | |
| SCHEMBL4265224 | 0.84 | S1PR1 (0.69) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605269-B2 | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-20 | — | — | US | claimed |
| US-20080318955-A1 | Novel Thiophene Derivatives as Sphingosine-1-Phosphate-1 Receptor Agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-12-25 | — | — | US | claimed |
| EP-1863474-B1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | EP | claimed |
| EP-1863474-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| WO-2006100633-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
| US-7605269-B2 | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-20 | — | — | US | disclosed |
| US-20080318955-A1 | Novel Thiophene Derivatives as Sphingosine-1-Phosphate-1 Receptor Agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1863474-B1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1863474-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100633-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318955-A1 | Novel Thiophene Derivatives as Sphingosine-1-Phosphate-1 Receptor Agonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.